Results 101 to 110 of about 5,159 (158)

PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study. [PDF]

Eur Heart J Suppl
Gatto L, Di Bitonto MP, Scalia L, Biccirè FG, Prati F.   +4 more
europepmc   +1 more source

Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. [PDF]

J Saudi Heart Assoc
AlHabeeb W, Alamri H, Elbadawi H, AlRuthia YS, Alharbi W, Alshammeri O, Tash A, Almoziny S, Kholaif N, Halawani H, AlMahdi F, Yar W, Alhabib KF.   +12 more
europepmc   +1 more source

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. [PDF]

Lipids Health Dis
Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B.   +12 more
europepmc   +1 more source

Non-Responder to Inclisiran and Evolocumab-A Female Patient with Heterozygous Familial Hypercholesterolemia and Statin Intolerance. [PDF]

Diseases
Muszyński P, Chlabicz M, Kruszyńska J, Wilk-Śledziewska K, Kazberuk P, Musiałowska D, Groth M, Dudzińska K.   +7 more
europepmc   +1 more source

New-onset vitiligo following proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab: A possible immune-mediated adverse effect. [PDF]

JAAD Case Rep
Umaña Mejia CA, Olvera Morales M, Jurado Orozco A, Burgos JD.   +3 more
europepmc   +1 more source

Advanced therapy in familial hypercholesterolemia. [PDF]

Can Fam Physician
Gao E, Brunham LR, Goldman RD.
europepmc   +1 more source

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. [PDF]

Korean Circ J
Roh JW, Lee OH, Kim Y, Heo SJ, Im E, Cho DK.   +5 more
europepmc   +1 more source

Effect of evolocumab on the gut microbiota in patients with acute myocardial infarction. [PDF]

J Med Microbiol
Zou J, Peng Y, Cai H, Zhong Q, Zhu N, Gu W, Yang F, Shi T, Yang S, Chen L.   +9 more
europepmc   +1 more source

Alirocumab <i>versus</i> Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis. [PDF]

Curr Cardiol Rev
Cleto AS, Schirlo JM, Machozeki J, Martins CM.   +3 more
europepmc   +1 more source

Dose Up-Titration of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Markedly Elevated Lipoprotein(a) in a Patient With Familial Hypercholesterolemia: A Case Report. [PDF]

Cureus
Suzuki N, Kishi H.
europepmc   +1 more source